Using a new treatment to boost the immune response against pancreatic cancer
Recombinant Interleukin-33 Immunotherapy for Pancreatic Cancer
This study is testing a new treatment for pancreatic cancer that uses a special protein to help boost your immune system so it can better fight the cancer, and it's designed for people with pancreatic ductal adenocarcinoma who want to improve their chances of recovery.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10908417 on NIH RePORTER |
What this research studies
This research investigates a novel immunotherapy approach for pancreatic cancer, specifically targeting the activation of immune cells to enhance the body's natural defenses against tumors. The study focuses on the use of recombinant interleukin-33 (rIL33) to stimulate immune responses in patients with pancreatic ductal adenocarcinoma, a type of cancer known for its poor immune response. By delivering rIL33, the researchers aim to increase the presence and activity of specific immune cells that can attack the cancer more effectively. The approach combines this treatment with existing therapies to maximize its effectiveness and improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who have limited treatment options due to the aggressive nature of the disease.
Not a fit: Patients with other types of cancer or those who do not have pancreatic ductal adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with pancreatic cancer, potentially improving survival rates and quality of life.
How similar studies have performed: Other research has shown promising results with similar immunotherapy approaches in different cancer types, indicating potential for success in this novel application.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Balachandran, Vinod P — Sloan-Kettering Inst Can Research
- Study coordinator: Balachandran, Vinod P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.